Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
1 additional grant classified as “Other” (multi-disciplinary, infrastructure, etc.).
Funding by Fiscal Year
NIH fiscal year (Oct–Sep)
$3.5M
FY22
$3.6M
FY23
$5.4M
FY24
$7.8M
FY25
By Funding Mechanism
R01
9
R21
5
R03
2
R44
2
F30
1
F32
1
Funding Gap Analysis
Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Oropharynx Squamous Cell Carcinoma. Strongest funded area: Translational / Drug Development. Largest gap: Translational / Drug Development.
Basic ScienceFunded, Few Publications
5 funded grants in Basic Science but only 1 related publication found for oropharynx squamous cell carcinoma. This may indicate early-stage research that hasn't yet produced published results.
Translational / Drug DevelopmentFunded, Few Publications
7 funded grants in Translational / Drug Development but only 0 related publications found for oropharynx squamous cell carcinoma. This may indicate early-stage research that hasn't yet produced published results.
Adjacent Research(7 grants)
These grants mention Oropharynx Squamous Cell Carcinoma as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.
